Zealand Pharma A/S (0NZU)

209.00
+4.30(+2.10%)
  • Volume:
    17,058
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    209.00 - 209.00

0NZU Overview

Prev. Close
204.7
Day's Range
209-209
Revenue
134.25M
Open
202.35
52 wk Range
70.05-210.6
EPS
-25.77
Volume
17,058
Market Cap
10.77B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
32,519
P/E Ratio
-7.02
Beta
1.06
1-Year Change
55.68%
Shares Outstanding
51,405,298
Next Earnings Date
09 Mar 2023
What is your sentiment on Zealand Pharma?
or
Market is currently closed. Voting is open during market hours.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S Company Profile

Employees
237
Market
Denmark

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company’s pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Read More

Analyst Price Target

Average235.60 (+12.41% Upside)
High284.4114
Low171
Price209.6
No. of Analysts9
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy